Takara Bio (4974) Stock Overview
Engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
4974 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Takara Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥826.00 |
| 52 Week High | JP¥1,177.00 |
| 52 Week Low | JP¥711.00 |
| Beta | 0.34 |
| 1 Month Change | 5.90% |
| 3 Month Change | 0.98% |
| 1 Year Change | -28.98% |
| 3 Year Change | -61.63% |
| 5 Year Change | -72.26% |
| Change since IPO | 58.85% |
Recent News & Updates
Recent updates
Some Investors May Be Willing To Look Past Takara Bio's (TSE:4974) Soft Earnings
May 22
Takara Bio (TSE:4974) Has Announced A Dividend Of ¥17.00
Mar 12Takara Bio (TSE:4974) Has Announced A Dividend Of ¥17.00
Feb 18Earnings Update: Takara Bio Inc. (TSE:4974) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Feb 16Takara Bio (TSE:4974) Has Affirmed Its Dividend Of ¥17.00
Jan 31Takara Bio (TSE:4974) Is Paying Out A Dividend Of ¥17.00
Jan 17Some May Be Optimistic About Takara Bio's (TSE:4974) Earnings
Nov 20Takara Bio (TSE:4974) Is Paying Out A Dividend Of ¥17.00
Nov 11Shareholder Returns
| 4974 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 0.5% | -1.0% | 0.4% |
| 1Y | -29.0% | -8.5% | -0.3% |
Return vs Industry: 4974 underperformed the JP Biotechs industry which returned -10.1% over the past year.
Return vs Market: 4974 underperformed the JP Market which returned -0.4% over the past year.
Price Volatility
| 4974 volatility | |
|---|---|
| 4974 Average Weekly Movement | 2.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4974 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4974's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,779 | Tsuyoshi Miyamura | www.takara-bio.com |
Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; genome-editing research reagents; iPS cell research reagents; and products for stem cell culturing and induction of differentiation under the TaKaRa, Clontech, and Cellartis brand names. It also provides contract services for regenerative medicine products, such as manufacturing of viral vectors and gene-transduced cells, quality and safety testing, and cell banking; and contract services for gene analysis and testing, including sequencing, intestinal flora analysis, comprehensive analysis of cancer-associated genes, and cell line creation through genome editing.
Takara Bio Inc. Fundamentals Summary
| 4974 fundamental statistics | |
|---|---|
| Market cap | JP¥99.46b |
| Earnings (TTM) | JP¥1.04b |
| Revenue (TTM) | JP¥45.04b |
Is 4974 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4974 income statement (TTM) | |
|---|---|
| Revenue | JP¥45.04b |
| Cost of Revenue | JP¥18.97b |
| Gross Profit | JP¥26.07b |
| Other Expenses | JP¥25.03b |
| Earnings | JP¥1.04b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 08, 2025
| Earnings per share (EPS) | 8.65 |
| Gross Margin | 57.88% |
| Net Profit Margin | 2.31% |
| Debt/Equity Ratio | 0% |
How did 4974 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/18 14:10 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Takara Bio Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Yen Ting Chen | Credit Suisse |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |